1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21363
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorPavlidis, N.en
dc.contributor.authorTerret, C.en
dc.contributor.authorBauer, J.en
dc.contributor.authorFiedler, W.en
dc.contributor.authorSchoffski, P.en
dc.contributor.authorRaoul, J. L.en
dc.contributor.authorHess, D.en
dc.contributor.authorSelvais, R.en
dc.contributor.authorLacombe, D.en
dc.contributor.authorBachmann, P.en
dc.contributor.authorFumoleau, P.en
dc.date.accessioned2015-11-24T19:14:40Z-
dc.date.available2015-11-24T19:14:40Z-
dc.identifier.issn0959-8049-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21363-
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/*drug therapyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Agents/*administration & dosage/adverse effects/pharmacokineticsen
dc.subjectDisease Progressionen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectGlucose/analogs & derivativesen
dc.subjectHumansen
dc.subjectIfosfamide/analogs & derivativesen
dc.subjectInfusions, Intravenousen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPancreatic Neoplasms/*drug therapyen
dc.subjectPhosphoramide Mustards/*administration & dosage/adverse effects/pharmacokineticsen
dc.subjectProspective Studiesen
dc.subjectTreatment Outcomeen
dc.titleGlufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development groupen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/14556925-
heal.identifier.secondaryhttp://ac.els-cdn.com/S0959804903006294/1-s2.0-S0959804903006294-main.pdf?_tid=05b9b2b6ce8eed635fd141cf9fb66f09&acdnat=1333702811_8b856e6815e294d62b882fbb20543193-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2003-
heal.abstractThe activity of glufosfamide (beta-D-glucopyranosyl-N,N'-di-(2-chloroethyl)-phosphoric acid diamide) against pancreatic cancer was investigated in a multicentre, phase II clinical study. Chemotherapy-nai;ve patients with advanced or metastatic disease were treated with glufosfamide (5 g/m(2)) using a 1-h intravenous (i.v.) infusion every 3 weeks. Patients were randomised between active-hydration and normal fluids to evaluate the nephroprotective effect of forced diuresis. Patients experiencing >0.4 mg/dl (>35 micromol/l) increase in serum creatinine compared with their baseline value were taken off treatment for safety reasons. The evaluation of response was according to the Response evaluation criteria in solid tumours (RECIST). Blood sampling was performed for pharmacokinetic analyses. 35 patients from 13 institutions were registered over a 13-month period. A total of 114 treatment cycles (median 3, range 1-8) were administered to 34 patients; 18 patients were allocated to the hydration arm. Overall haematological toxicity was mild. Metabolic acidosis occurred in 2 patients treated in the active-hydration arm, grade 3 hypokalaemia was recorded in 5 patients and grade 3 hypophosphataemia in 4 patients. One patient had a grade 4 increase in serum creatinine level, concomitantly to disease progression. Active-hydration did not show a nephroprotective effect and the plasma pharmacokinetics (Pk) of glufosfamide was not significantly influenced by hydration. Two confirmed partial remissions (PR) were reported (response rate 5.9%, 95% Confidence Interval (CI) 0.7-19.7%) and 11 cases obtained disease stabilisation (32.4%). An extra mural review panel confirmed all of the responses. Median overall survival was 5.3 months (95% CI 3.9-7.1) and time to progression (TTP) was 1.4 months (95% CI 1.3-2.7). In conclusion, glufosfamide administered using a 1-h infusion every 3 weeks has a modest activity in advanced pancreatic adenocarcinoma. Haematological toxicity is particularly mild, but regular monitoring of renal function is recommended.en
heal.journalNameEur J Canceren
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Briasoulis-2003-Glufosfamide adminis.pdf218.17 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons